XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

BURNABY, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 pm Eastern time.

A webcast will be available on the investors section of the Xenon website at  and will be available for replay following the event.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit .

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:

Jodi Regts

Xenon Pharmaceuticals Inc.

Phone: 604.484.3353

Email:

EN
01/06/2020

Underlying

XENEXenon Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
TOL TOLL BROTHERS INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
DNLI DENALI THERAPEUTICS INC
TLS TELOS
ALCC ALTC ACQUISITION CORP
GETY GETTY IMAGES HOLDINGS INC
ORKA ORUKA THERAPEUTICS INC
08/12/25 August 12, 2025 1 EN
Laura Chico
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
08/12/25 August 12, 2025 1 EN
 PRESS RELEASE
Free
XENE Xenon Pharmaceu...

Xenon Reports Second Quarter 2025 Financial Results & Business Update

Xenon Reports Second Quarter 2025 Financial Results & Business Update – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOB...

August 11, 2025 1 EN
Laura Chico
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
08/08/25 August 8, 2025 1 EN
 PRESS RELEASE
Free
XENE Xenon Pharmaceu...

Xenon to Report Q2 2025 Financial Results on August 11, 2025

Xenon to Report Q2 2025 Financial Results on August 11, 2025 VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, August 11, 2025. Conference Call/Webcast Information: Date: Monday, August 11, 2025Time: 4:30 pm Eastern Time...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch